南财智讯1月30日电，广生堂发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 亏损1.70亿元—2.40亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 1.78亿元—2.48亿元。本报告期内，公司业绩亏损主要影响原因如下：1、报告期内，公司始终坚持创新 药发展战略，持续研发投入以快速推进创新药临床研究，且受前期固定资产投资较大等因素影响，公司 研发费用和管理费用保持在较高水平。截止目前，在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III 期临床试验已完成526例受试者入组，达到临床方案设定的计划目标入组数，后续将继续推进受试者入 组工作，预计于2026年2月中旬完成全部入组，最终入组人数可能在原计划目标基础上有少部分增加。 创新药研发周期长，投入大，风险高，容易受到多方面因素的影响，临床研究存在研究进度和结果不及 预期甚至失败的风险，后续能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风 险。2、公司基于谨慎性原则，对报告期末合并报表范围内无形资产、存货、固定资产等资产进行减值 测试，对发生减值的资产计提减值准备。3、报告期内，预计非经常 ...

Core Viewpoint - Jincheng Pharmaceutical has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a decrease of 73.07% to 79.67% year-on-year [1] Financial Performance Summary - The company anticipates a net profit attributable to shareholders of 40 million to 53 million yuan for 2025, which represents a substantial decrease compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 28 million and 37 million yuan, reflecting a year-on-year decline of 79.43% to 84.44% [1] Reasons for Performance Change - The primary reasons for the decline in performance include: 1. A slowdown in product market demand, intense industry competition, and the impact of national centralized procurement policies, leading to a decrease in both prices and sales volume for certain products in the intermediate and formulation segments [1] 2. An increase in asset impairment provisions for 2025 compared to the previous year, in response to industry and market changes [1] 3. The need for the company's subsidiaries, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Guangdong Landu Pharmaceutical Co., Ltd., to pay back taxes from previous years [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 12 million and 16 million yuan [1]

Core Viewpoint - The company, Borui Pharmaceutical, anticipates a significant decline in its annual net profit for 2025, projecting a range of 41.3 million to 61.9 million yuan, which represents a year-on-year decrease of 67.28% to 78.17% [1] Financial Performance - The expected non-GAAP net profit is forecasted to be between 430,000 and 2.49 million yuan, reflecting a year-on-year reduction of 86.21% to 97.62% [1] - The decline in revenue and gross profit is attributed to changes in flu trends, competitive landscape, and customer demand [1] Operational Factors - Increased depreciation from construction projects being put into service and heightened R&D investments are contributing to the profit decline [1] Research and Development - The company has multiple ongoing research projects, including the completion of patient enrollment for the Phase III clinical trials of BGM0504 injection for type 2 diabetes and weight loss in China [1] - The oral BGM0504 tablet is also undergoing Phase I clinical trials in both China and the United States [1] - However, the commercialization of innovative drugs remains uncertain as they are still in the early stages of development [1]

Group 1 - The company Sital is expected to achieve a net profit attributable to shareholders of 10 million to 13 million yuan for the year 2025, marking a turnaround from a loss in the previous year [1] - The improvement in performance is primarily due to the continuous optimization of the company's revenue structure, with an increase in the sales proportion of high-margin products [1] - Cost control has been enhanced through process optimization and refined supply chain management, contributing to an increase in gross profit during the reporting period [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers operating at full capacity, with orders scheduled until 2028 [1] - Employees are working in three shifts, and production lines are running 24 hours a day to meet the high demand [1]

Core Viewpoint - Haizheng Shengcai (688203) expects a significant decline in net profit for the fiscal year 2025, projecting a profit of 7.5 million to 9.5 million yuan, representing a year-on-year decrease of 73.24% to 78.88% [2] Financial Performance - The company faces downward pressure on product sales prices, which has compressed the gross profit margin [2] - A decrease in interest income and foreign exchange gains has led to an increase in financial expenses for the period [2] - The transition of some construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further squeezing profits [2]

Core Viewpoint - The company, Haizheng Shengcai (688203.SH), expects a significant decline in net profit for the year 2025, projecting a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company is projected to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million to 7.5 million yuan, reflecting a year-on-year decrease of 75.98% to 82.39% [1] Operational Insights - The company has seen steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - Despite the growth in sales revenue due to deepening and expanding the domestic market, the company faces downward pressure on product sales prices due to market competition [1] Financial Challenges - There has been a year-on-year decrease in interest income and foreign exchange gains, leading to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - The company, Fu'an Pharmaceutical, anticipates a significant decline in net profit for the fiscal year 2025, projecting a range of 70 million to 100 million yuan, which represents a year-on-year decrease of 64.26% to 74.99% due to the implementation of national drug procurement policies leading to substantial price reductions of its main products [1] Financial Performance - The expected net profit for 2025 is estimated to be between 70 million and 100 million yuan [1] - This projection indicates a decline of 64.26% to 74.99% compared to the previous year [1] Market Conditions - The implementation of national drug procurement is causing a significant drop in sales prices of the company's main products [1] - As a result, the company's operating revenue is decreasing, leading to continued pressure on profit margins [1]

Core Viewpoint - The company, Haizheng Shengcai, expects a significant decline in net profit for the year 2025, projecting a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Projections - The net profit attributable to the parent company is estimated to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between 5.5 million to 7.5 million yuan, reflecting a reduction of 23.7289 million to 25.7289 million yuan compared to the same period last year [1]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 7.5 million to 9.5 million yuan, which represents a year-on-year decrease of 73.24% to 78.88% [1] Group 1 - The company cites market competition as a key factor leading to downward pressure on product sales prices, which in turn compresses gross profit margins [1] - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the current period [1] - Ongoing construction projects related to fundraising have been capitalized, resulting in increased depreciation and tax expenses, further impacting current profits [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 10 to 13 million yuan in 2025, marking a turnaround from a loss of 49.099 million yuan in the previous year, primarily due to revenue structure optimization and cost control measures [1] Financial Performance - The projected net profit for 2025 is between 10 million and 13 million yuan, compared to a loss of 49.099 million yuan in the previous year, indicating a significant improvement [1] - The expected non-recurring net profit is estimated to be between 2.5 million and 5.5 million yuan [1] - The improvement in performance is attributed to an increase in the sales proportion of high-margin products and enhanced cost control efficiency [1] Cost and Financial Management - Cost control measures have led to improved efficiency in managing expenses, contributing to an increase in gross profit scale [1] - A reduction in financing costs and foreign exchange gains have resulted in decreased financial expenses [1]